Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | ABL2 | P42684 | 1/20 | 0.58 |
| ▸ | VCP | P55072 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GALR2 | O43603 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881805 | 1.00 | FBP1 (0.63) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL2027152 | 0.84 | EGFR (0.72) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL1975634 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL1976021 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL1975635 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL1976020 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL2027151 | 0.84 | EGFR (0.72) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL3100099 | 0.81 | VCP (0.77) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL3100101 | 0.81 | VCP (0.77) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL6815701 | 0.81 | ALDH1A1 (0.58) | FBP1EGFRABL1ABL2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116613-B | Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof | 湘潭大学 | 2021-04-23 | — | — | CN | claimed |
| CN-111116613-A | Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof | 湘潭大学 | 2020-05-08 | — | — | CN | claimed |
| CN-111116613-B | Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof | 湘潭大学 | 2021-04-23 | — | — | CN | disclosed |
| CN-111116613-A | Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof | 湘潭大学 | 2020-05-08 | — | — | CN | disclosed |
| US-9206124-B2 | Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-3978143-A | PROCESS FOR PREPARING DIARYLDINITROETHYLENES | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | FBP1 4633/4885EGFR 17/4885ABL1 211/4885 |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | FBP1 4708/4885EGFR 4676/4885ABL1 611/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | FBP1 4708/4885EGFR 4676/4885ABL1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.